New Taipei City, Taiwan, June 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (the “Company”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and…
Wed, 18 Jun 2025 14:20:00 GMT The Company has granted the underwriters an option, exercisable within 45 days from the date of the final prospectus, to purchase up to an additional 400,000 Ordinary Shares at the public offering ...
Mon, 16 Jun 2025 22:44:00 GMT The Offering is being conducted on a firm commitment basis. Joseph Stone Capital, LLC is acting as sole underwriter for the Offering (the“Underwriter”). Sichenzia Ross Ference Carmel LLP is acting as ...
Wed, 02 Apr 2025 17:00:00 GMT Jyong Biotech Ltd. (Revived IPO) (MENS) expects to raise $22 million in an IPO on the week of April 7th, IPO Scoop reports. The company plans to issue 2,700,000 shares at a price of $7.50-$8.50 ...
